ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.
The renin-angiotensin-aldosterone system has an important role in the progression of both diabetic and non-diabetic nephropathy. COOPERATE was set up to determine whether dual blockade of angiotensin-converting-enzyme (ACE) and the AT-1 receptor was more efficacious than either ACE inhibition or AT-1 antagonism alone in non-diabetic renal disease. The combined primary end point was of time to doubling of serum creatinine concentration or end stage renal disease. By year 3, 10 of 85 (11%) of the combination patients had reached the primary end point. This was significantly less than the 20 of 86 (23%) and 20 of 85 (23%) in the losartan and trandolapril groups, respectively. Combination treatment should be considered in non-diabetic renal disease especially if the disease is progressing with ACE treatment alone.
Doggrell
Sheila A
SA
School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia. s_doggrell@yahoo.com
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D023381:Endpoint Determination; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D019808:Losartan / Q000009:adverse effects / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril; D003404:Creatinine; D019808:Losartan